A Neato Cell: Data Show Favorable Efficacy, Toxicity For Arcellx/Gilead Myeloma CAR-T

 
• By Alaric DeArment

Anito-cel showed strong efficacy in heavily pretreated patients despite characteristics predicting poorer performance, but none of the atypical neurotoxicities that have appeared with other BCMA CAR-Ts.

Gilead's Kite Pharma is partnered with Arcellx on the development of anito-cel, also known as CART-ddBCMA • Source: Scrip

More from Clinical Trials

More from R&D